{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:02:45Z","timestamp":1791914565180,"version":"4.3.4"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T00:00:00Z","timestamp":1256860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.<\/jats:p><jats:p><jats:bold>Objective:\u2002<\/jats:bold> To determine whether risk for adverse neonatal outcomes are reduced by stopping SSRI use before the end of pregnancy.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> Using population health data, maternal health and prenatal SSRI prescriptions were linked to neonatal birth records (<jats:italic>N<\/jats:italic>\u2003=\u2003119\u2003547) (1998\u20132001). Neonates SSRI\u2010exposed in the last 14\u2003days (L14) of gestation were compared with infants who had gestational exposure, but not during the last 14\u2003days (NL14). Propensity score matching was used to control for potential confounders (total exposure, maternal health characteristics).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Increased risk for neonatal respiratory distress was present where L14 exposure occurred compared with risk where exposure stopped before L14. However, controlling for potential maternal and neonatal confounders, differences disappeared.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Controlling for maternal illness severity, reducing exposure to SSRI\u2019s at the end of pregnancy had no significant clinical effect on improving neonatal health. These findings raise the possibility that some adverse neonatal outcomes may not be an acute pharmacological condition such as toxicity or withdrawal.<\/jats:p>","DOI":"10.1111\/j.1600-0447.2009.01490.x","type":"journal-article","created":{"date-parts":[[2009,10,30]],"date-time":"2009-10-30T07:29:16Z","timestamp":1256887756000},"page":"471-479","source":"Crossref","is-referenced-by-count":109,"title":["A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health"],"prefix":"10.1111","volume":"121","author":[{"given":"W.","family":"Warburton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hertzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. F.","family":"Oberlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,4]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.19.2372"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351402"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.160.2.173"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052744"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041100"},{"key":"e_1_2_9_7_2","unstructured":"Food and Drug Administration.Evaluation of Human Pregnancy Outcome Data. http:\/\/www fda gov\/cder\/guidance\/index htm 1999Available from: URL:http:\/\/www.fda.gov\/cder\/guidance\/index.htm"},{"key":"e_1_2_9_8_2","unstructured":"Health Canada.Health Canada advises of potential adverse effects of SSRIs and other anti\u2010depressants on newborns.http:\/\/www.hc\u2010sc.gc.ca\/ahc\u2010asc\/media\/advisories\u2010avis\/_2004\/2004_44\u2010eng.php. 4 A.D. Aug 9. Report No.:http:\/\/www.hc\u2010sc.gc.ca\/english\/protection\/warnings\/2004\/2004_44.htm."},{"key":"e_1_2_9_9_2","unstructured":"US Food and Drug Administration.FDA Medwatch Drug Alert on Effexor (venlafaxine HCI) and Effexor XR (venlafaxine HCI)http:\/\/www.fda.gov\/medwatch\/safety\/2004\/safety04.htm#effexor. 2004 Jun 3. Report No.:http:\/\/www.fda.gov\/medwatch\/safety\/2004\/safety04.htm#effexor."},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0214"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200412000-00016"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-200204000-00008"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.2.368"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.898"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.12.2055"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.037101"},{"key":"e_1_2_9_17_2","unstructured":"Teleplan Record Specifications Version 4.0.http:\/\/www.hlth.gov.bc.ca\/msp\/infoprac\/diagcodes\/index.html. http:\/\/www hlth gov bc ca\/msp\/infoprac\/teleplanspecs\/ch1 pdf page 27 2004Available from: URL:http:\/\/www.hlth.gov.bc.ca\/msp\/infoprac\/diagcodes\/index.html."},{"key":"e_1_2_9_18_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF03403934","article-title":"Creating a population\u2010based linked health database: a new resource for health services research","volume":"89","author":"Chamberlayne R","year":"1998","journal-title":"Can J Public Health"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/026988119801200311"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20144"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000089629.62884.22"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06071172"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360404"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1998)8:1 <27::AID-DA5>3.0.CO;2-K"},{"key":"e_1_2_9_26_2","first-page":"2081","article-title":"Are the new SSRIs safe for pregnant women?","volume":"44","author":"Kulin NA","year":"1998","journal-title":"Can Fam Physician"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.720"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300823"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.6.1001"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002007"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02538.x"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00221-3"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216040-00006"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(99)00046-3"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/fn.85.2.F145g"},{"issue":"7","key":"e_1_2_9_37_2","first-page":"11","article-title":"Antidepressant discontinuation: a review of the literature","volume":"58","author":"Lejoyeux M","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01441-5"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0420"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-2133"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.158.4.312"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115060-00005"},{"key":"e_1_2_9_43_2","first-page":"443","article-title":"Compliance with SSRI medication during 6\u2003months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations","volume":"82","author":"Reis M","year":"2004","journal-title":"J Affect Disord"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.12.1933"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.2009.01490.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.2009.01490.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:37:09Z","timestamp":1697452629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.2009.01490.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,4]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1600-0447.2009.01490.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.2009.01490.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,4]]}}}